Sex Hormone-Binding Globulin and Cardiac Function in Men with Heart Failure: Possible Role of Diabetes

Viktor Čulić1,2, Željko Bušić3, Riccardo Vio4

  • 1Department of Cardiology and Angiology, University Hospital Centre Split, Šoltanska 1, 21000 Split, Croatia.

PubMed

Insights

In men with heart failure (HF) and type 2 diabetes mellitus (T2DM), higher sex hormone-binding globulin (SHBG) is linked to worse heart function. Testosterone, however, shows a protective effect in these patients.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Disorders

Background:

  • The relationship between sex hormone-binding globulin (SHBG) and heart failure (HF) is debated, especially in patients with type 2 diabetes mellitus (T2DM).
  • Understanding these associations is crucial for managing cardiovascular health in diabetic populations.

Purpose of the Study:

  • To investigate the association between SHBG levels and clinical/echocardiographic parameters of HF in men.
  • To differentiate these associations based on the presence or absence of T2DM.

Main Methods:

  • Prospective collection of data from 215 male patients hospitalized for acute HF.
  • Assessment included baseline characteristics, risk factors, medications, serum SHBG, total testosterone, and echocardiographic parameters.
  • Multivariate analysis was used to determine independent associations.

Main Results:

  • Patients with T2DM exhibited older age, higher BMI, and more severe HF symptoms (NYHA class).
  • A significant correlation between SHBG and left ventricular ejection fraction (LVEF) was found only in T2DM patients (r = 0.456).
  • Increased SHBG independently predicted lower LVEF in T2DM patients (ß = -0.542), while higher testosterone predicted higher LVEF (ß = 0.531).

Conclusions:

  • In men with HF and T2DM, SHBG demonstrates an independent adverse impact on LVEF, explaining 12.5% of its variance.
  • Conversely, testosterone appears to have a beneficial role in preserving LVEF in this cohort.
  • Further research into the subcellular mechanisms of SHBG in diabetic heart disease is warranted.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
278
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
295
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K